Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.
The Foodsmart program is changing how people think about food by using smart tech to make nutrition a lot more personal and practical. These tools don’t just help people track what they eat—they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback